Pain relief drug for mast cell disorder fails to reach goal
Symptom relief
Terminated
This study tested whether FSD201 could reduce daily pain in adults with chronic widespread pain caused by mast cell activation syndrome. Only 2 people enrolled before the trial was stopped early. Participants took FSD201 or a placebo for up to 56 days and reported their pain leve…
Phase: PHASE2 • Sponsor: Quantum Biopharma • Aim: Symptom relief
Last updated May 14, 2026 12:06 UTC